Epistemis

CNS Demyelinating Diseases

Demyelinating CNS Diseases — Expert Level Reference

How it begins

From oligodendrocyte and the molecular architecture of the node of Ranvier to plaque, budding and silent progression. Multiple sclerosis, neuromyelitis optica, MOGAD, acute disseminated encephalomyelitis and metabolic-toxic and infectious demyelination, with their biology, immunopathology, detailed diagnostic criteria, neuroimaging, cerebrospinal fluid, biomarkers and the modern therapeutic arsenal...

What it covers

  1. Concept, terminology and classification of demyelinating diseases
  2. · Operational etiopathogenic classification
  3. · An essential historical note
  4. Myelin: cell biology, biochemistry and the architecture of the node of Ranvier
  5. · The oligodendrocyte versus the Schwann cell
  6. · Biochemistry: lipids and proteins of central myelin
  7. · The molecular architecture of the node of Ranvier
  8. · Myelin as trophic support of the axon
  9. Pathophysiology of demyelination, conduction block and remyelination
  10. · From healthy fiber to clinical deficit
  11. · Clinical correlates of altered physiology
  12. · Remyelination: why it exists and why it fails
  13. Multiple sclerosis: epidemiology
  14. · Distribution by age, sex and time
  15. · The latitudinal gradient and migration studies
  16. Etiology and risk factors of multiple sclerosis
  17. · Genetic susceptibility
  18. · Environmental factors
  19. Immunopathology of multiple sclerosis
  20. · The immunological cascade: from outside to inside the CNS
  21. · Lassmann-Lucchinetti patterns
  22. Neuropathology: plaque and gray matter pathology
  23. · Classification of plates according to their activity
  24. · The revolution in gray matter pathology
  25. Clinical manifestations: the topographic syndromes of the flare
  26. · Optic neuritis
  27. · Myelitis (partial)
  28. · Brainstem and cranial nerve syndromes
  29. · Cerebellar syndromes
  30. Symptoms throughout the disease: fatigue, cognition, mood and paroxysmal phenomena
  31. · Fatigue
  32. · Cognitive impairment
  33. · Psychiatric symptoms
  34. · Bladder, intestinal and sexual dysfunction
  35. · Pain, spasticity and paroxysmal phenomena
  36. Phenotypes and evolutionary course
  37. · From subclinical risk to progressive forms
  38. · Disability measurement and prognosis
  39. Diagnosis: McDonald's criteria
  40. · Operational definitions
  41. · The contribution of oligoclonal bands (McDonald 2017)
  42. · Diagnostic scenarios according to clinical presentation
  43. Complementary tests: MRI, cerebrospinal fluid, evoked potentials and OCT
  44. · Magnetic resonance: the paraclinical pillar
  45. · Cerebrospinal fluid
  46. · Evoked potentials and optical coherence tomography
  47. · Biomarkers in blood
  48. Differential diagnosis and red flags
  49. · Main imitators (“MS mimics”)
  50. Treatment of acute flare
  51. · Corticosteroids at high doses
  52. · Plasmapheresis and rescue options
  53. Disease-modifying therapies (TME/DMT)
  54. · Pharmacological overview
  55. · Screening, monitoring and the threat of PML
  56. Symptomatic treatment and rehabilitation
  57. · Management by symptoms
  58. Special situations: pregnancy, pediatric MS, vaccination and comorbidity
  59. · MS and pregnancy
  60. · Pediatric MS
  61. · Vaccination and immunization
  62. Neuromyelitis optica spectrum disorders (NMOSD)
  63. · Immunopathology
  64. · Cardinal clinical syndromes
  65. · Diagnosis (international criteria 2015)
  66. Anti-MOG antibody disease (MOGAD)
  67. · Clinical phenotypes according to age
  68. Acute disseminated encephalomyelitis (ADEM) and post-infectious demyelination
  69. · Clinical and differential features
  70. Focal demyelinating syndromes and variants of multiple sclerosis
  71. · "Isolated" demyelinating syndromes
  72. · Fulminant and atypical variants of MS
  73. Metabolic, toxic and infectious demyelination
  74. · Osmotic demyelination syndrome (myelinolysis)
  75. · Other non-immune acquired demyelination
  76. Diagnostic integration and demyelinating emergencies
  77. · Mental approximation algorithm
  78. · Comparison of the three major immune-mediated entities
  79. · Demyelinating emergencies that do not allow delay

The complete study guide is in the app

This page summarizes the outline. The full interactive study guide —with high-yield diagrams, clinical tables, and board review cases— can be read inside Epistemis, completely offline and ad-free.

Subject
Neurology
Category
Clinical Specialties
Type
Study Guide
Sections
79
Reviewed
2026-08-02
Download Epistemis